Quanxin Biotech announced that the company and Roche reached an exclusive global cooperation and licensing agreement. According to the agreement, the company granted Roche exclusive global rights to develop, produce and commercialize the QX031N. The company expects to receive a one-time, non-refundable, and non-deductible down payment of up to $995 million in milestone payments relating to product development, regulatory approval, and commercialization, as well as gradient royalties for potential future product sales.

Zhitongcaijing · 10/28/2025 09:57
Quanxin Biotech announced that the company and Roche reached an exclusive global cooperation and licensing agreement. According to the agreement, the company granted Roche exclusive global rights to develop, produce and commercialize the QX031N. The company expects to receive a one-time, non-refundable, and non-deductible down payment of up to $995 million in milestone payments relating to product development, regulatory approval, and commercialization, as well as gradient royalties for potential future product sales.